IDPCTC, pediatric cerebral tumors classification
This panel includes the IDBRAF-SNC, IDFGFR1-SNC and the IDH3F3A kit
A new classification for CNS tumors released by the WHO in 2016 considers histopathology and molecular information to establish an integrated diagnostic that should lead a better characterization of CNS tumors. This diagnostic approach for CNS plays a crucial role in determining the subsequent treatment plan, so must be carry-out with the most accurate techniques.
Regarding techniques used for this molecular characterization, many of them require high amount of DNA and RNA, need highly purified DNA, parameters that could not always be achieve using FFPE sample. In addition, most techniques cannot answer to all questions, and force laboratories to use various approaches.
Digital PCR (dPCR) is highly sensitive, works in presence of inhibitors, allows copy number variation and gene rearrangement detection using only DNA sample. We have developed a dPCR multiplex panel for the molecular characterization of pediatric CNS tumors detecting mutations on BRAF with KIAA-BRAF fusion (IDBRAF-SNC) ; FGFR1 and its duplication (IDFGFR1-SNC) and H3F3A (IDH3F3A) using only DNA.
This kit can be used on circulating DNA and DNA isolated from formaldehyde-fixed and paraffin-embedded tissues (FFPE).
It is compatible with the following instruments: Digital droplet PCR QX200 (Biorad) and Naica system digital droplet PCR (Stilla). For others, please contact us.
All the kits included in the panel can be sold separately
|Reference and format||IDPCTC includes for 25 preps:
|Matrix||Circulating DNA extracted from plasma and FFPE|
|Application||digital PCR (dPCR)|
|Duration of the protocol||4h (QX200-96 samples) and 2h (Naica-12 samples)|